Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CINK-CAR: CNS administration of CART-NKG2D or NKIL15 cells in pediatric and young adult high-grade CNS tumors
2026-525876-24-00Phase 2Authorised
- Sponsor
- Hospital Universitario La Paz
- Start
- Jul 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in central nervous system tumor, medulloblastoma, Atypical teratoid rhabdoid tumor (ATRT) and 2 more comparing CART45RA-NKG2D CNS arm with NKIL15 CNS arm (2 arms). Primary endpoint: Safety and tolerability of CART45RA-NKG2D or NKIL15. Planned start Jul 2026; status: authorised.
02
Drugs
CART45RA-NKG2DNKIL15
03
Conditions
central nervous system tumormedulloblastomaAtypical teratoid rhabdoid tumor (ATRT)ependymomaglioma
Beyond the preview
Go deeper on 2026-525876-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525876-24-00.